The largest database of trusted experimental protocols

Ssea4 fitc

Manufactured by BD

SSEA4-FITC is a fluorescent-conjugated antibody that detects the stage-specific embryonic antigen 4 (SSEA4), a carbohydrate marker expressed on the surface of undifferentiated human embryonic stem cells and certain types of cancer cells. This product is designed for use in flow cytometry and other cell-based applications to identify and characterize SSEA4-positive cell populations.

Automatically generated - may contain errors

5 protocols using ssea4 fitc

1

Comprehensive Stem Cell Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were fixed in BD CytofixTM fixation buffer (BD Biosciences) for 15 min at room temperature and then washed three times with BD perm/wash buffer (BD Biosciences) every 10 min. After a 30 min incubation with perm/wash buffer at room temperature, cells were stained with the following conjugated primary antibodies and incubated overnight at 4°C: OCT3/4-FITC (1:100; BD Pharmingen), NANOG-PE (1:100; BD Pharmingen), SOX2-PE (1:50; BD Biosciences), SSEA3-PE (1:100; BD Pharmingen), SSEA4-FITC (1:100; BD Biosciences), TRA-1-60-FITC (1:100; BD Pharmingen), and βIII-tubulin-FITC (1:100; BD Biosciences). Cells were imaged using fluorescence microscopy (Leica, Wetzlar, Germany).
+ Open protocol
+ Expand
2

Immunophenotyping of PVC from Normal and GDM Pregnancies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single cell suspensions were prepared from normal pregnant women and GDM patient-derived HUCPVC (hereafter called N-PVC and GDM-PVC) cultures by dissociation with 0.05% trypsin-EDTA. The cells were resuspended in 1% FBS-PBS and were stained for 1 hr with the following fluorochrome-conjugated anti-human antibodies: CD31-phycoerythrin (PE), CD34-luorescein-isothiocyanate (FITC), CD45-allophycoerythrin (APC), SSEA-4-FITC, CD146-FTIC, CD44-APC and CD90-APC (all BD Biosciences) or their corresponding isotype controls. After immunostaining, the cells were incubated with the viability dye 7-aminoactinomycin D (7AAD) to exclude dead cells. Data was analyzed using FACSCanto II (BD Biosciences) and FlowJo software.
+ Open protocol
+ Expand
3

Pluripotency and Hematopoietic Differentiation Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the pluripotency of iPS cells, the antibodies TRA1-60-PE (Cat Nr. MA1-023-PE, eBioscience) and SSEA4-FITC (Cat Nr. 560126, BD biosciences, BD) were used. Dead cells were excluded from the analysis by 4′,6-diamidino-2-phenylindole (DAPI; 1μg/ml) (Cat Nr. D3571, Thermo Fisher Scientific) staining. For detection of hematopoietic progenitor cells, the antibodies CD33-BV421 (Cat Nr. 366622, BioLegend, BL), CD34-PE-Cy7 (Cat Nr. 343615, BL), KDR-AF647 (Cat Nr. 359909, BL), CD43-PE (Cat Nr. 343204, BL), CD41a-FITC (Cat Nr. 303703, BL), CD235a-FITC (Cat Nr. 349103, BL), CD45-BV510 (Cat Nr. 103138, BL) and 7-AAD (Cat Nr. 420404, BL) were used as an “early-stage” multicolor hematopoietic cell panel. For the detection of mature myeloid cells, the antibodies CD15-PE (Cat Nr. 301905, BL), CD16-FITC (Cat Nr. 302005, BL), CD14-APC-H7 (Cat Nr. 367117, BL), CD45-BV510 (Cat Nr. 103138, BL), CD33 BV-421 (Cat Nr. 366622, BL) and 7-AAD (Cat Nr. 420404, BL) were used as a “late-stage” multicolor myeloid differentiation panel. Anti-mouse IgGk beads were used for compensation. Antibodies and beads for flow cytometry were purchased from BD Biosciences unless otherwise indicated. Samples were analyzed using a FACS Canto II flow cytometer (Becton-Dickinson) and FlowJo software (FLOWJO, LLC, Ashland, OR).
+ Open protocol
+ Expand
4

Characterization of Human Umbilical Cord Perivascular Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HUCPVCs were dissociated into single cells using trypsin-EDTA and resuspended in
1% FBS-PBS. The cells were filtered through a 70 µm cell strainer and reacted
with the following antibodies conjugated with fluorochrome for 1 hr at 4℃:
CD31-phycoerythrin (PE), CD34-fluorescein-isothiocyanate (FITC),
CD45-allophycoerythrin (APC), CD44-APC, CD90-APC, CD146-FITC, and SSEA-4-FITC
(all, BD Biosciences). The dead cells were excluded with 7-aminoactinomycin D.
Stained cells were analyzed using the FACSCanto II (BD Biosciences) and data
were analyzed by FlowJo software (FlowJo).
+ Open protocol
+ Expand
5

Pluripotency and Hematopoietic Differentiation Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the pluripotency of iPS cells, the antibodies TRA1-60-PE (Cat Nr. MA1-023-PE, eBioscience) and SSEA4-FITC (Cat Nr. 560126, BD biosciences, BD) were used. Dead cells were excluded from the analysis by 4′,6-diamidino-2-phenylindole (DAPI; 1μg/ml) (Cat Nr. D3571, Thermo Fisher Scientific) staining. For detection of hematopoietic progenitor cells, the antibodies CD33-BV421 (Cat Nr. 366622, BioLegend, BL), CD34-PE-Cy7 (Cat Nr. 343615, BL), KDR-AF647 (Cat Nr. 359909, BL), CD43-PE (Cat Nr. 343204, BL), CD41a-FITC (Cat Nr. 303703, BL), CD235a-FITC (Cat Nr. 349103, BL), CD45-BV510 (Cat Nr. 103138, BL) and 7-AAD (Cat Nr. 420404, BL) were used as an “early-stage” multicolor hematopoietic cell panel. For the detection of mature myeloid cells, the antibodies CD15-PE (Cat Nr. 301905, BL), CD16-FITC (Cat Nr. 302005, BL), CD14-APC-H7 (Cat Nr. 367117, BL), CD45-BV510 (Cat Nr. 103138, BL), CD33 BV-421 (Cat Nr. 366622, BL) and 7-AAD (Cat Nr. 420404, BL) were used as a “late-stage” multicolor myeloid differentiation panel. Anti-mouse IgGk beads were used for compensation. Antibodies and beads for flow cytometry were purchased from BD Biosciences unless otherwise indicated. Samples were analyzed using a FACS Canto II flow cytometer (Becton-Dickinson) and FlowJo software (FLOWJO, LLC, Ashland, OR).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!